Real Life Experience with Individualized Doses of Incobotulinumtoxina in Patients with Severe Spasticity Due to Acquired Brain Injury

Main Article Content

Maysa Hayani Al-nisr Noemi Correas Alguacil

Abstract

The objective of the present study was to evaluate the effectiveness and tolerability of incobotulinumtoxinA, at doses according to individual needs, in 10 patients with acquired brain injury and severe upper and lower limb spasticity. Patients received a multipattern periodic treatment with ultrasound-guided injections of incobotulinumtoxinA at doses of 800-900 U in the upper and lower limbs. The mean number of injection cycles per patient was 4.2. The 0-10 visual analogue scale for pain score decreased significantly from pre-injection (mean: 4.7) to four-week post-injection (mean: 0.7). Similarly, the mean Ashworth Scale score (muscular tone assessment) at four-week post-injection (mean: 1.4) was significantly lower than at injection (mean: 2.5). Except for two patients in one pattern, all cases showed an improvement in passive range of motion assessments using goniometry. All patients reported maximum satisfaction with the treatment, all reporting “much improved” after the treatment. No treatment-related adverse effects were observed during the study. Individualized doses of incobotulinumtoxinA are effective and well-tolerated for this type of patients and allow better management of their severe spasticity. Therefore, individualization of doses should be taken into account for optimizing clinical outcomes and improving the patients’ treatment satisfaction.

Article Details

How to Cite
HAYANI AL-NISR, Maysa; CORREAS ALGUACIL, Noemi. Real Life Experience with Individualized Doses of Incobotulinumtoxina in Patients with Severe Spasticity Due to Acquired Brain Injury. Medical Research Archives, [S.l.], v. 10, n. 12, dec. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3342>. Date accessed: 29 jan. 2023. doi: https://doi.org/10.18103/mra.v10i12.3342.
Section
Research Articles

References

1. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J. Neurotrauma. 2008;25:719–738. doi: 10.1089/neu.2008.0586.
2. Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disability and Rehabilitation. 2006;28(13-14):891-897. doi:10.1080/09638280500535165
3. Pandyan A, Gregoric M, Barnes M, Wood D, Wijck F, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability and Rehabilitation. 2005;27(1-2):2-6. doi:10.1080/09638280400014576
4. McGuire J. Epidemiology of spasticity in the adult and child. In: Brashear A editor(s). Spasticity: Diagnosis and Management. 2nd Edition. New York (NY): Demos Medical Publishing, 2016.
5.Elovic EP, Munin MC, Kanovsk ! ý P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. Muscle Nerve 2016;53:415–421.
6.Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010;257:1330–1337.
7. Santamato A, Ranieri M, Solfrizzi V, Lozupone M, Vecchio M, Daniele A, Greco A, Seripa D, Logroscino G, Panza F. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opin Drug Metab Toxicol. 2016; 12(8); 843-846.
8. Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology. 2017;88(14):1321-1328. doi:10.1212/WNL.0000000000003789
9. Ianieri G, Marvulli R, Gallo GA, Fiore P, Megna M. "Appropriate treatment" and therapeutic window in spasticity treatment with incobotulinumtoxinA: From 100 to 1000 units. Toxins (Basel). 2018;10(4):140. doi:10.3390/toxins10040140
10. Dressler D, Altavista MC, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm (Vienna). 2021;128(3):321-335. doi:10.1007/s00702-021-02312-4
11. Turcu-Stiolica A, Subtirelu MS, Bumbea AM. Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center. Brain Sci. 2021 ;11(7):934. doi: 10.3390/brainsci11070934.
12. Hefter H, Rosenthal D, Jansen A, Brauns R, Ürer B, Bigalke H, et al. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. J.Neurol 2022; doi: 10.1007/s00415-022-11395-2.
13. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-26. doi: 10.1212/WNL.0000000000002560.
14. Ro T, Ota T, Saito T, Oikawa O. Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy. J Stroke Cerebrovasc Dis. 2020;29(1):104481. doi: 10.1016/j.jstrokecerebrovasdis.
15. Cordero-García C, Sández de Tejada Sánchez MM. Benefit and Safety of Incobotulinumtoxina for Early Management of Post-Stroke Spasticity In A Patient With Sars-Cov-2: A Case Report. JRM-CC. 2021; 4(1000065): doi: 10.2340/20030711-1000065
16. Paba Dotes AB and De Torres-Gárcia I. Management of Spasticity Caused by Thrombotic Brain Injury with Incobotulinumtoxina in a Young Patient: A New Paradigm, Medical Research Archives, [online] 2022; 10(6). https://doi.org/10.18103/m ra.v10i6.2836
17. Heinen F, Kanovský P, Schroeder AS, Chambers HG, Dabrowski E, Geister TL, Hanschmann A, et al. IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study. J Pediatr Rehabil Med. 2021;14(2):183-197. doi: 10.3233/PRM-210040.
18. Wissel J, Camões-Barbosa A, Comes G, Althaus M, Scheschonka A and Simpson D. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins 2021, 13, 887. https://doi.org/10.3390/toxins13120887
19. Dressler D, Adib Saberi F. Rehabilitation of dystonia. In: Chien HF, Barsottini O (eds) Movement disorders rehabilitation. Springer, New York, 2017: 67–82
20. Dressler D, Adib Saberi F, Rosales RL. Botulinum toxin therapy of dystonia. J Neural Transm (Vienna). 2021; 128(4):531-537. doi: 10.1007/s00702-020-02266-z.